{"id":"prograf-xl","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Prograf-XL works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes. This action prevents the activation of T-lymphocytes and subsequent immune response. As a result, Prograf-XL reduces the risk of organ rejection in transplant patients.","oneSentence":"Prograf-XL is an immunosuppressant that inhibits calcineurin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:00.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"}]},"trialDetails":[{"nctId":"NCT05622318","phase":"PHASE2","title":"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-08-29","conditions":"Graft-versus-host Disease","enrollment":56},{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT03680092","phase":"PHASE2","title":"Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dimitrios Tzachanis, MD PhD","startDate":"2019-11-26","conditions":"GVHD, Hematologic Neoplasms","enrollment":43},{"nctId":"NCT02723591","phase":"PHASE4","title":"To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-09-09","conditions":"Kidney Transplantation","enrollment":599},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT02555787","phase":"","title":"Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2015-03-05","conditions":"Kidney Transplantation","enrollment":4430},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT00611351","phase":"PHASE2","title":"Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2005-06-07","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":5},{"nctId":"NCT03194321","phase":"PHASE4","title":"Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-09-11","conditions":"End Stage Renal Disease","enrollment":20},{"nctId":"NCT03828058","phase":"PHASE2","title":"Envarsus XL Immunosuppression Following Liver Transplantation","status":"COMPLETED","sponsor":"Methodist Healthcare","startDate":"2019-04-01","conditions":"Recipients of Liver Transplant","enrollment":110},{"nctId":"NCT03263052","phase":"","title":"Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2017-07-01","conditions":"Disorder Related to Renal Transplantation","enrollment":40},{"nctId":"NCT02953873","phase":"PHASE4","title":"Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2017-05-05","conditions":"Immunosuppression","enrollment":25},{"nctId":"NCT04154735","phase":"PHASE2","title":"Autologous Transplant Targeted Against Crohn's","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT02444143","phase":"PHASE4","title":"A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-05","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT00619398","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-01","conditions":"Liver Transplantation","enrollment":172},{"nctId":"NCT02339246","phase":"PHASE3","title":"Pharmacokinetic Comparison Of All FK-506 Formulations","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2015-01","conditions":"Renal Failure","enrollment":32},{"nctId":"NCT00717678","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":73},{"nctId":"NCT02221583","phase":"PHASE4","title":"Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2014-05","conditions":"End Stage Renal Disease","enrollment":26},{"nctId":"NCT00865137","phase":"PHASE3","title":"An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-09","conditions":"Kidney Transplantation","enrollment":27},{"nctId":"NCT00064701","phase":"PHASE3","title":"Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-06","conditions":"Kidney Transplantation","enrollment":668},{"nctId":"NCT00282256","phase":"PHASE2","title":"A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT00282243","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-02","conditions":"Liver Transplantation","enrollment":70},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70},{"nctId":"NCT01681134","phase":"PHASE1","title":"A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Canada, Inc.","startDate":"2012-07","conditions":"Healthy","enrollment":19},{"nctId":"NCT00720408","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Liver Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tacrolimus extended release","FK506E","MR4","FK506XL"],"phase":"phase_3","status":"active","brandName":"Prograf-XL","genericName":"Prograf-XL","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prograf-XL is an immunosuppressant that inhibits calcineurin. Used for Prevention of organ rejection in kidney transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}